검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Talimogene Laherparepvec (Talimogene Laherparepvec) SOLTI Breast Cancer Research Group·Melanoma ORR 100% |
|---|---|
Overview Program | Talimogene Laherparepvec |
Overview Company | SOLTI Breast Cancer Research Group |
Overview Modality | CGT |
Overview Target | Melanoma |
Overview Indication | Breast Cancer |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | , and emerging therapeutic potential of oncolytic viruses (OVs) in the management of HNSCC, with an emphasis on ongoing trials, approved agents, and future directions |
MoA Biomarker | HER2-negative breast cancer follow |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Re-evaluating melanoma treatment: a comparative look at herpes simplex virus and coxsackievirus oncolytic therapies in advanced melanoma: a meta-analysis of clinical trials.. Advanced melanoma, a highly lethal skin cancer, causes most skin cancer-related deaths. Oncolytic monotherapy or alongside immune checkpoint inhibitors (ICIs) is emerging as a promising treatment. Evaluating the therapeutic b… |
Clinical Primary efficacy | ORR 100% |
Clinical ORR | 100% |
Clinical Result source | ClinicalTrials.gov NCT03714828 |
Clinical Data Tier / Score | A · 40 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (2일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Talimogene Laherparepvec (Talimogene Laherparepvec) SOLTI Breast Cancer Research Group·Melanoma ORR 100% |
|---|---|
Overview Program | Talimogene Laherparepvec |
Overview Company | SOLTI Breast Cancer Research Group |
Overview Modality | CGT |
Overview Target | Melanoma |
Overview Indication | Breast Cancer |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | , and emerging therapeutic potential of oncolytic viruses (OVs) in the management of HNSCC, with an emphasis on ongoing trials, approved agents, and future directions |
MoA Biomarker | HER2-negative breast cancer follow |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Re-evaluating melanoma treatment: a comparative look at herpes simplex virus and coxsackievirus oncolytic therapies in advanced melanoma: a meta-analysis of clinical trials.. Advanced melanoma, a highly lethal skin cancer, causes most skin cancer-related deaths. Oncolytic monotherapy or alongside immune checkpoint inhibitors (ICIs) is emerging as a promising treatment. Evaluating the therapeutic b… |
Clinical Primary efficacy | ORR 100% |
Clinical ORR | 100% |
Clinical Result source | ClinicalTrials.gov NCT03714828 |
Clinical Data Tier / Score | A · 40 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (2일 전) |
추천 비교
추천 비교